e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ligand Pharmaceuticals Incorporated - Common Stock
(NQ:
LGND
)
180.99
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ligand Pharmaceuticals Incorporated - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Why Is Ligand Pharmaceuticals Stock Trading Higher Today?
February 27, 2024
Ligand Pharmaceuticals beats Q4 2023 sales estimates at $28.1 million, with strong core Captisol and royalty figures. CEO Todd Davis highlights transformative 2023 and optimistic guidance for 2024.
Via
Benzinga
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 27, 2024
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.
Via
Benzinga
Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday
February 27, 2024
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday.
Via
Benzinga
Topics
Stocks
Earnings Scheduled For February 27, 2024
February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
Via
Benzinga
Ligand Pharmaceuticals's Earnings: A Preview
February 26, 2024
Via
Benzinga
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) Making Surprising Moves in Tuesday Session
February 27, 2024
Via
Investor Brand Network
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 27, 2024
Via
Benzinga
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
February 22, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Where Ligand Pharmaceuticals Stands With Analysts
September 19, 2023
Via
Benzinga
Analyst Expectations for Ligand Pharmaceuticals's Future
August 23, 2023
Via
Benzinga
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
February 16, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
February 13, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 01, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum
January 05, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance
December 12, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City
December 06, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications
December 01, 2023
From
Palvella Therapeutics
Via
GlobeNewswire
Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's
November 28, 2023
Merck & Co Inc (NYSE: MRK) released results from the STRIDE-3 Phase 3 trial evaluating V116, the company's investigational 21-valent
Via
Benzinga
Ligand Reports Third Quarter 2023 Financial Results
November 08, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million
November 01, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand To Report Third Quarter 2023 Financial Results On November 8
October 25, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
October 18, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ligand Acquires Assets of Novan, Inc. for $12.2 Million
September 27, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Appoints Martine Zimmermann to its Board of Directors
September 26, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
September 22, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand’s Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control
September 21, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pharma Updates Annual Guidance As It Spins Out Pelican Subsidiary
September 19, 2023
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) entered into a merger agreement under which its subsidiary, Pelican Technology Holdings Inc, has become a wholly owned subsidiary of Primrose Bio...
Via
Benzinga
Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio
September 18, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
September 01, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
Facebook
Twitter
YouTube